Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|August 1, 2006
Psychiatric Issues in Emergency Care Settings
- Psychiatric Issues in Emergency Care Settings Vol 5 No 3
- Volume 5
- Issue 3
Acute and Posttraumatic Stress DisordersPharmacotherapies for Acute and Chronic Responses to Psychological TraumaPTSD in the Emergency SettingStress Disorders: Patient Assessment and Management
Advertisement
Editorial
GLENN W. CURRIER, MD, MPH
Posttraumatic Stress Disorder
NEGAR FANI, MS, BENJAMIN M. HAMPSTEAD, MS, J. DOUGLAS BREMNER, MD
Clinical Case Presentations
NEGAR FANI, MS, BENJAMIN M. HAMPSTEAD, MS, J. DOUGLAS BREMNER, MD
Commentary
PETER F. BUCKLEY, MD
also inside: Reader Forum, Literature Highlights
Articles in this issue
about 20 years ago
METHAMPHETAMINE ABUSEabout 20 years ago
Acute and Posttraumatic Stress Disordersabout 20 years ago
Is an electronic medical record useful in the PES setting?about 20 years ago
PTSD in the Emergency Settingabout 20 years ago
Stress Disorders: Patient Assessment and ManagementAdvertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
5